Loading
1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Treated as poor-risk non-seminoma: four cycles of BEP or VIP with care for bleeding, resection of residual disease, high-dose chemotherapy or trials for refractory disease.
Bleomycin is the 'B' in BEP for testicular cancer and ABVD for Hodgkin lymphoma; its unique danger is scarring of the lungs, so lung function is monitored and it is often dropped when safe.
Etoposide is a chemotherapy from the mayapple plant, essential to curing testicular cancer (BEP), treating small-cell lung cancer, lymphomas, childhood sarcomas and leukaemias, and used in transplant conditioning.
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
No headline result recorded yet.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Ototoxicity · US label: up to 31% after a single 50 mg/m2 dose (tinnitus or high-frequency hearing loss); hearing loss in children estimated at 40-60% | 31% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Febrile neutropenia (with doxorubicin) · EORTC 62012, intensified doxorubicin plus ifosfamide arm (103 of 224); 13% with doxorubicin alone | - | 46% |
| Central nervous system toxicity, including encephalopathy · Ifosfamide monotherapy trials pooled in the label (154 of 1001) | 15.4% | - |
| Visible blood in the urine (macroscopic haematuria) · With mesna, ifosfamide monotherapy trials pooled in the label (5 of 97); 11.1% without mesna | 5.2% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.